Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following vaccines are given through the intramuscular route? 1. BCG vaccine 2. Hepatitis B vaccine 3. Pentavalent vaccine 4. Inactivated Polio vaccine

2, 3 and 4. ***2, 3 and 4*** - The **Hepatitis B vaccine**, **Pentavalent vaccine** (DPT-Hib-HepB), and **Inactivated Polio Vaccine (IPV)** are all administered via the **intramuscular (IM)** route to ensure proper absorption and immune response. - Intramuscular injection is preferred for these vaccines to deliver antigens directly into muscle tissue, promoting effective antigen-presenting cell uptake. *1, 2 and 3* - This option incorrectly includes the **BCG vaccine**, which is administered intradermally, not intramuscularly. - The **BCG vaccine** creates a localized immune response in the skin, which is crucial for its protective mechanism against tuberculosis. *1, 3 and 4* - This combination is incorrect because it includes the **BCG vaccine**, which is given intradermally. - Administering **BCG intramuscularly** could lead to adverse reactions and reduce vaccine efficacy. *1, 2 and 4* - This option is incorrect as it again includes the **BCG vaccine**, which is administered **intradermally**. - Proper route of administration is critical for vaccine safety and effectiveness, and only **Hepatitis B, Pentavalent, and IPV** are given intramuscularly among the listed choices.

Q: Which one of the following statements regarding the composition of common crystalloid solutions is correct ?

Hartmann’s solution contains 111 meq/L of Cl. ***Hartmann’s solution contains 111 meq/L of Cl*** - **Hartmann's solution** (Lactated Ringer's) typically contains **111 mmol/L** (or meq/L) of chloride. - Its electrolyte composition aims to mimic plasma more closely than normal saline, with **lower chloride content** to reduce the risk of hyperchloremic acidosis. *Hartmann’s solution contains 111 meq/L of Na* - Hartmann's solution contains approximately **130 meq/L of Na**, not 111 meq/L. - The sodium concentration is higher than 111 meq/L to maintain **isotonicity** and match plasma osmolality. *Normal saline contains 130 meq/L of Cl* - **Normal saline (0.9% NaCl)** contains **154 meq/L of Cl**, which is significantly higher than 130 meq/L. - Its high chloride content can lead to **hyperchloremic metabolic acidosis** if administered in large volumes. *Normal saline contains 100 meq/L of Na* - **Normal saline (0.9% NaCl)** contains **154 meq/L of Na**, not 100 meq/L [1]. - This higher sodium concentration contributes to its **isotonicity** with plasma [1].

Q: Choose the correct options regarding the route of administration and bioavailability. A- Intravenous =1 B- 0.75< Oral <1 C-0.75 <IM ≤ 1 D- 0.75<SC ≤ 1 IM - Intramuscular SC- Subcutaneous

A, C, D. ***A, C, D*** - Intravenous (IV) administration has **100% bioavailability** because the drug enters the systemic circulation directly, bypassing any absorption barriers. - Intramuscular (IM) and subcutaneous (SC) routes generally have **high bioavailability**, often between 75% and 100%, as drugs are absorbed directly into the bloodstream without first-pass metabolism. *A and D* - While options A and D are correct, this choice is incomplete as option C is also a correct statement regarding bioavailability. - IM administration typically results in high systemic bioavailability, similar to SC, making its exclusion here incorrect. *A and C* - While options A and C are correct, this choice is incomplete as option D is also a correct statement regarding bioavailability. - Subcutaneous administration also generally results in high bioavailability, as absorption tends to be complete. *A, B, D* - While options A and D are correct, option B is typically incorrect for oral bioavailability. - Oral bioavailability of many drugs is often less than 0.75 (75%) due to factors like **first-pass metabolism** and incomplete absorption in the gastrointestinal tract.

Q: What would happen to the half-life and plasma concentration of a drug which follows first-order kinetics, if the dose is doubled?

Half - life remains the same and plasma concentration doubles. ***Half - life remains the same and plasma concentration doubles*** - In **first-order kinetics**, drug elimination is proportional to the **plasma concentration**, meaning a constant *fraction* of the drug is eliminated per unit of time. - Doubling the dose will **double the initial plasma concentration**, but the **half-life** (time taken for plasma concentration to halve) remains constant because the *rate of elimination proportionally increases* with concentration. *Half - life and plasma concentration remains the same* - This would only be true if the dose was not changed, or if the drug followed **zero-order kinetics** and the elimination system was already saturated, which is not the case here. - If the plasma concentration remained the same after doubling the dose, it would imply either no absorption or extremely rapid elimination, contradicting typical first-order drug behavior. *Half - life doubles and plasma concentration remains the same* - For **half-life to double**, there would need to be a **decrease in drug clearance** or an *increase in volume of distribution*, not simply a dose increase. - If plasma concentration remained the same despite a doubled dose, it would suggest a **major increase in clearance** or volume of distribution, which is not stated. *Half life and plasma concentration doubles* - While plasma concentration doubles with a doubled dose in **first-order kinetics**, the **half-life remains constant**. - Half-life is an **intrinsic pharmacokinetic parameter** determined by clearance and volume of distribution, not by the administered dose in first-order kinetics.

Q: Purpose of adding zinc to insulin in commercial preparations for treatment of diabetes mellitus is:-

To make it long acting. ***To make it long acting*** - **Zinc** is added to insulin formulations, particularly **neutral protamine Hagedorn (NPH) insulin**, to create larger crystal complexes [1]. - These larger complexes **slow down the absorption** of insulin from the subcutaneous injection site, thereby prolonging its duration of action [2]. *To make it short acting* - **Short-acting insulins** like regular insulin are not formulated with zinc, as their purpose is rapid onset and a shorter duration. - Adding zinc would counteract the desired rapid-acting pharmacokinetic profile. *To make it fast acting* - **Fast-acting insulins** (insulin analogs) have specific amino acid modifications that alter their self-association properties to ensure rapid absorption, not the addition of zinc [2]. - Zinc actually works against the goal of fast action by promoting aggregation. *Addition of zinc makes the insulin effective orally* - Insulin is a **peptide hormone** and is generally destroyed by digestive enzymes in the gastrointestinal tract, making oral administration ineffective regardless of zinc presence [3]. - Efforts to create oral insulin involve complex delivery systems, not simple zinc addition.

Q: True for lithium:

Narrow therapeutic index. ***Narrow therapeutic index*** - Lithium has a **narrow therapeutic index**, meaning the difference between its effective and toxic doses is small. - This necessitates **close monitoring of serum lithium levels** to ensure efficacy and prevent toxicity. *Can be given safely in renal dysfunction* - Lithium is **primarily excreted renally**, and its clearance is directly proportional to creatinine clearance. - Therefore, it **should be used with caution** (or avoided) in patients with renal dysfunction due to increased risk of toxicity. *Protein bound* - Lithium is **not protein-bound**; it exists as a free ion in the blood. - This characteristic contributes to its rapid distribution and excretion. *Delayed absorption* - Lithium is **rapidly and almost completely absorbed** from the gastrointestinal tract. - Peak plasma concentrations are usually reached within 1-2 hours for immediate-release preparations.

Q: The shortest acting opioid is:-

Remifentanil. ***Remifentanil*** - **Remifentanil** is an **ultra-short-acting opioid** due to its unique metabolism by **non-specific plasma and tissue esterases**. - Its rapid metabolism results in a very short context-sensitive half-time, meaning its effects **terminate quickly** regardless of infusion duration. *Alfentanil* - **Alfentanil** is a **short-acting opioid** but its duration of action is longer than remifentanil. - It is eliminated primarily by **hepatic metabolism**, which is slower than esterase-based metabolism. *Fentanyl* - **Fentanyl** is a **potent synthetic opioid** with an intermediate duration of action. - Its elimination is dependent on **hepatic metabolism**, and it has a longer context-sensitive half-time compared to remifentanil. *Sufentanil* - **Sufentanil** is a **very potent opioid** with a longer duration of action than fentanyl and alfentanil. - Its metabolism is hepatic, leading to a **longer elimination half-life** and thus a more prolonged effect.

Q: Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

Competitive inhibition. ***Competitive inhibition*** - Atorvastatin is a **statin**, which acts as a **competitive inhibitor** of **HMG-CoA reductase**, the rate-limiting enzyme in cholesterol synthesis. - It competes with the natural substrate, HMG-CoA, for binding to the **active site of the enzyme**, thereby reducing cholesterol production. *Uncompetitive* - **Uncompetitive inhibitors** bind only to the **enzyme-substrate complex**, not to the free enzyme. - This type of inhibition is characterized by a decrease in both **apparent Vmax** and **apparent Km**. *Noncompetitive inhibition* - **Noncompetitive inhibitors** bind to an allosteric site on the enzyme, distinct from the active site, and can bind to either the **free enzyme or the enzyme-substrate complex**. - This leads to a decrease in the **apparent Vmax** but does not affect Km. *Irreversible inhibition* - **Irreversible inhibitors** form a **strong covalent bond** with the enzyme, permanently inactivating it. - Statins do not form covalent bonds with HMG-CoA reductase; their inhibition is **reversible** upon drug discontinuation.

Q: Therapeutic index of a drug is an indicator of:-

Safety. ***Safety*** - The **therapeutic index (TI)** is a ratio comparing the **toxic dose (TD50)** to the **effective dose (ED50)**: TI = TD50/ED50. - It indicates the **margin of safety** of a drug—the wider the margin between therapeutic and toxic doses, the safer the drug. - A **high therapeutic index** means greater safety; a **low therapeutic index** means the drug has a narrow safety margin. *Potency* - **Potency** refers to the amount of drug needed to produce a given effect, represented by the **ED50**. - The therapeutic index is a **ratio**, not a measure of potency alone. - A highly potent drug can still have a narrow therapeutic index if its toxic dose is close to its effective dose. *Efficacy* - **Efficacy** describes the **maximum therapeutic effect** a drug can produce, irrespective of dose. - The therapeutic index does not quantify maximum effect but rather the **safety margin** within which therapeutic effects can be achieved. *All of these* - While potency and efficacy are important drug properties, the therapeutic index **specifically indicates safety**. - TI is not a composite measure of all drug properties—it is exclusively a safety parameter.

Question 1

Which of the following vaccines are given through the intramuscular route?

1. BCG vaccine
2. Hepatitis B vaccine
3. Pentavalent vaccine
4. Inactivated Polio vaccine

Accepted Answer

2, 3 and 4

Answer

1, 2 and 3

Answer

1, 3 and 4

Answer

1, 2 and 4

Question 2

Which one of the following statements regarding the composition of common crystalloid solutions is correct ?

Accepted Answer

Hartmann’s solution contains 111 meq/L of Cl

Answer

Hartmann’s solution contains 111 meq/L of Na

Answer

Normal saline contains 130 meq/L of Cl

Answer

Normal saline contains 100 meq/L of Na

Question 3

Which of the following statements is correct regarding the given graph?

Accepted Answer

Drug 1 represents agonist and drug 4 represents inverse agonist

Answer

Drug 1 represents agonist and drug 2 represents inverse agonist

Answer

Drug 3 represents agonist and drug 4 represents inverse agonist

Answer

Drug 2 represents partial agonist and drug 3 represents inverse agonist

Question 4

Choose the correct options regarding the route of administration and bioavailability.
A- Intravenous =1
B- 0.75< Oral <1
C-0.75 <IM ≤ 1
D- 0.75<SC ≤ 1
IM - Intramuscular
SC- Subcutaneous

Accepted Answer

A, C, D

Answer

A and D

Answer

A and C

Answer

A, B, D

Question 5

What would happen to the half-life and plasma concentration of a drug which follows first-order kinetics, if the dose is doubled?

Accepted Answer

Half - life remains the same and plasma concentration doubles

Answer

Half - life and plasma concentration remains the same

Answer

Half - life doubles and plasma concentration remains the same

Answer

Half - life and plasma concentration doubles

Question 6

Purpose of adding zinc to insulin in commercial preparations for treatment of diabetes mellitus is:-

Accepted Answer

To make it long acting

Answer

To make it short acting

Answer

To make it fast acting

Answer

Addition of zinc makes the insulin effective orally

Question 7

True for lithium:

Accepted Answer

Narrow therapeutic index

Answer

Can be given safely in renal dysfunction

Answer

Protein bound

Answer

Delayed absorption

Question 8

The shortest acting opioid is:-

Accepted Answer

Remifentanil

Answer

Fentanyl

Answer

Alfentanil

Answer

Sufentanil

Question 9

Atorvastatin is used as an anti-dyslipidemic drug. These drugs inhibit their target enzyme by:-

Accepted Answer

Competitive inhibition

Answer

Noncompetitive inhibition

Answer

Irreversible inhibition

Answer

Uncompetitive inhibition

Question 10

Therapeutic index of a drug is an indicator of:-

Accepted Answer

Safety

Answer

All of these

Answer

Potency

Answer

Efficacy

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?